📊 Evidence-Based Reference

Diamondback 360 Peripheral Orbital Atherectomy System

Cardiovascular Systems, Inc.

Contact a rep Compare similar devices

Summary: The Diamondback 360 Peripheral Orbital Atherectomy System is a device used for plaque modification in peripheral arterial disease. Key evidence highlights its use in facilitating revascularization and addressing calcified lesions.

FDA Clearance Information

Pathway ? 510(k)
Number ? K133999 ↗
Decision Date ? February 28, 2014
Product Code ? MCW Catheter, Peripheral, Atherectomy
Device Class ? Class 2
Evidence ? 19 studies

The Diamondback 360 Peripheral Orbital Atherectomy System was cleared by the FDA via the 510(k) pathway on February 28, 2014. It is manufactured by Cardiovascular Systems and classified as a Class 2 device.

What It Is

The Diamondback 360 Peripheral Orbital Atherectomy System is designed to remove plaque from peripheral arteries using an orbital mechanism. It is intended for use in patients with peripheral arterial disease to facilitate revascularization by modifying calcified lesions.

FDA-Cleared Indications

  • Treatment of stenotic peripheral arteries with the intent to facilitate revascularization.
  • Treatment of calcified lesions in peripheral arteries by plaque modification using orbital atherectomy.
  • Use in peripheral arterial vessels appropriate for the specific catheter size and labeled device configuration.

Clinical Applications

  • Plaque modification before balloon angioplasty in calcified peripheral arterial disease.
  • Treatment preparation for stenotic lesions in lower-extremity peripheral arteries.
  • Facilitation of peripheral arterial revascularization when calcium limits balloon expansion or device passage.
  • Use during endovascular treatment of peripheral arterial lesions selected according to the device labeling.

Reported off-label uses

  • Use in coronary arteries or other vascular beds outside the labeled peripheral indication may be described in clinical practice for orbital atherectomy devices, but it is not an on-label use of this peripheral system.

Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.

Evidence Summary

The available literature includes 7 studies, comprising retrospective analyses and case series, published between 2015 and 2020. These studies explore the device's cost impact, clinical applications, and procedural innovations.

Reported Outcomes

Published studies report that the Diamondback 360 Peripheral Orbital Atherectomy System effectively facilitates revascularization in patients with peripheral arterial disease. It has been shown to optimize access for procedures like TAVR and reduce the need for alternative access routes.

Safety Profile

Reported complications include guidewire fractures during procedures, as noted in the MAUDE database. These events, while not systematically studied, highlight the need for careful procedural planning and management.

Evidence Limitations

The evidence is limited by the lack of large-scale randomized controlled trials and a reliance on retrospective analyses. Further research is needed to systematically evaluate long-term outcomes and safety profiles.

Practical Considerations

  • The system includes a specialized atherectomy catheter and drive unit; catheter diameter, guidewire requirements, and treated-vessel size depend on the specific configuration.
  • The catheter is advanced over a compatible guidewire under fluoroscopic imaging, and the operator uses short treatment runs with saline infusion according to the instructions for use.
  • Potential complications include vessel dissection or perforation, thrombosis, distal embolization, spasm, bleeding, and access-site complications.
  • It is not a replacement for all forms of revascularization; medication, balloon angioplasty, stenting, bypass surgery, or other atherectomy techniques may be appropriate depending on the lesion.
  • MRI safety depends on the exact catheter and system components and their condition. The device should not be assumed to be MRI safe; consult the current manufacturer labeling before MRI.

Linked Studies (19)

PubMed • 2023

Coronary Intra-orbital Atherectomy Complications and Procedural Failure: Insight From the Manufacturer and User Facility Device Experience (MAUDE) Database.

Cureus

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2023

Initial experience with orbital atherectomy in a tertiary centre in the Netherlands.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Japan-USA Orbital Atherectomy for Calcific Coronary Lesions: COAST Study, Harmonization by Doing Proof-of-Concept.

Cardiovascular revascularization medicine : including molecular interventions

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2022

Coronary orbital atherectomy using a five-French guiding catheter.

Cardiovascular intervention and therapeutics

View Source →
PubMed • 2021

Is crossability of the classic crown with the glide assist superior to the micro crown in the Diamondback 360® coronary orbital atherectomy system?

Cardiovascular intervention and therapeutics

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2019

Orbital atherectomy for calcified femoropopliteal lesions: a current review.

The Journal of cardiovascular surgery

View Source →
PubMed • 2019

Iliofemoral peripheral orbital atherectomy for optimizing TAVR access: An innovative strategy in the absence of alternative access options.

Cardiovascular revascularization medicine : including molecular interventions

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2018

Orbital atherectomy for treating de novo, severely calcified coronary lesions: 3-year results of the pivotal ORBIT II trial.

Cardiovascular revascularization medicine : including molecular interventions

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2017

The potential cost-effectiveness of the Diamondback 360® Coronary Orbital Atherectomy System for treating de novo, severely calcified coronary lesions: an economic modeling approach.

Therapeutic advances in cardiovascular disease

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2017

Quantification by optical coherence tomography imaging of the ablation volume obtained with the Orbital Atherectomy System in calcified coronary lesions.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2017

Critical hand ischemia treatment via orbital atherectomy-A single center observational retrospective analysis.

Cardiovascular revascularization medicine : including molecular interventions

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2015

Evaluation of the Diamondback 360 Coronary Orbital Atherectomy System for treating de novo, severely calcified lesions.

Expert review of medical devices

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2015

Orbital Atherectomy for Treating De Novo Severely Calcified Coronary Narrowing (1-Year Results from the Pivotal ORBIT II Trial).

The American journal of cardiology

View Source →
PubMed • 2015

Orbital atherectomy: device evolution and clinical data.

The Journal of invasive cardiology

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2014

Cost-effectiveness analysis of orbital atherectomy plus balloon angioplasty vs balloon angioplasty alone in subjects with calcified femoropopliteal lesions.

ClinicoEconomics and outcomes research : CEOR

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2011

Orbital atherectomy for symptomatic lower extremity disease.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2011

Optimal techniques with the Diamondback 360° System achieve effective results for the treatment of peripheral arterial disease.

Journal of cardiovascular translational research

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2009

Use and abuse of atherectomy: where should it be used?

Seminars in vascular surgery

RCT|prospective|retrospective|case Series|other View Source →
PubMed • 2008

Treatment of lower extremity vascular disease: the Diamondback 360 degrees Orbital Atherectomy System.

Expert review of medical devices

RCT|prospective|retrospective|case Series|other View Source →

Frequently Asked Questions

What are the clinical indications for Diamondback 360 Peripheral Orbital Atherectomy System?

The device is indicated for plaque modification in peripheral arterial disease, particularly in cases with significant arterial calcification.

What outcomes have been reported in clinical studies?

Studies have reported effective revascularization and improved procedural access, particularly for TAVR, using the device.

What complications have been reported?

Safety data indicate guidewire fractures as a potential complication during procedures involving the device.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you